Abstract
Patients with medically inoperable early stage nonsmall cell lung cancer are now routinely offered definitive treatment with stereotactic body radiation therapy (SBRT), which achieves excellent local control and provides a 3-year survival on the order of 60%, with less than 5% chance of severe toxicity. 1,2 However, the same medical comorbidities that make patients inoperable, such as diabetes and hypertension, are also thought to increase the risk of toxicity from radiation therapy.3 In general the comorbidities that may predispose patients to greater toxicity involve microvascular pathology. Connective tissue disorders (CTDs), including scleroderma, systemic lupus erythematous (SLE), dermatomyositis, polymyositis, rheumatoid arthritis, Sjogren’s syndrome, and mixed CTDs, have traditionally been considered a relative contraindication to radiation therapy since the effects on normal tissues could possibly be severe.4,5 SBRT generally involves a tightly focused, ablativeintent dose of radiation to a small target, with rapid dose
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.